Allogeneic Stem Cell Transplantation Clinical Trial
Official title:
Association of Genetic Polymorphisms in the Interferon-λ Signaling Cascade and Immune Response After Vaccination
The following observational study will investigate whether the vaccine response (antibodies, T and B cells) after allogeneic stem cell transplantation is influenced by genetic polymorphisms in the interferon lambda signal.
The research project deals with one of the most important virological preventive measures after stem cell transplantation: vaccination against influenza viruses. Patients with allogeneic stem cell transplantation may experience serious complications of influenza and are at higher risk for inadequate response to the vaccine. The research project will make it possible, in a translational-medical orientation, to investigate the exact influence of genetic polymorphisms of the Interferon (IFN)-λ signalling cascade on the immune response after vaccination. This knowledge will make it possible to identify high-risk patients for a poor vaccination response before vaccination and to personalize the current vaccination strategy (intra-muscular injection), e.g. by subcutaneous vaccination, repeated administration of the vaccine or vaccine with adjuvants. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT01212796 -
Allo After Allo Stem Cell Transplantation Following Relapse After Allogeneic Transplant in Haematological Malignancies: Retrospective Results of the GETH
|
N/A | |
Terminated |
NCT01185223 -
Study Comparing Valganciclovir Versus Ganciclovir in Patients Following Allogeneic Stem Cell Transplantation
|
Phase 3 | |
Terminated |
NCT00737113 -
Recombinant Human Growth Hormone (RH-GH) For Accelerating Immune Reconstitution Post Unrelated Cord Blood Transplant
|
Phase 1 | |
Recruiting |
NCT06028828 -
Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT03964922 -
Immunoevasive Tactics Employed by Myeloid Malignancy After Allogeneic Stem Cell Transplantation
|
N/A | |
Completed |
NCT02273024 -
Exercise Prior to Allogeneic Hematologic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT06093334 -
Imaging of Chemotherapy-induced Morphological and Functional Lung Changes in Childhood ALL and HD
|
N/A | |
Recruiting |
NCT03286530 -
Ruxolitinib + Allogeneic Stem Cell Transplantation in AML
|
Phase 2 | |
Completed |
NCT01092026 -
Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells
|
N/A | |
Recruiting |
NCT01160952 -
Long-term Versus Short-term Sequential Therapy (Intravenous Itraconazole Followed by Oral Solution) of Itraconazole as Primary Prophylaxis in Patients Undergoing Allogeneic Stem Cell Transplantation
|
Phase 2 | |
Recruiting |
NCT00883714 -
Exercise During the Allogeneic Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT04628338 -
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
|
Early Phase 1 | |
Completed |
NCT06256341 -
HHV-6-specific T-cell Reconstitution Among Children and Adolescents After Allogeneic Stem.
|
||
Completed |
NCT05088941 -
Impact of COVID-19 Pandemic on Allogeneic Stem Cell Transplantation Organization : a French Experience
|
||
Not yet recruiting |
NCT06453460 -
Prospect Eval of Efficacy of CMV-TCIP Direct Letermovir Prophylax After Allogen Hemato Cell Transpla
|
Phase 2 | |
Recruiting |
NCT02533947 -
Cognition in Allogeneic Stem Cell Transplanted Patients and Sports
|
N/A | |
Completed |
NCT01560689 -
Inhaled BUDESONIDE/FORMOTEROL in Bronchiolitis Obliterans Following Stem Cell Transplantation
|
Phase 2 | |
Not yet recruiting |
NCT06297629 -
A Phase I/II Trial to Assess the Efficacy and Toxicity of ASTX727 (Oral Decitabine/Cedazuridine) for the Treatment of Hematological Neoplasms After Allogeneic Stem Cell Transplantation
|
Phase 2 | |
Completed |
NCT01929980 -
Bortezomib to Treat Significant Complication of HSCT
|
Phase 2 |